Tate & Lyle PLC (TATE)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 564.50 |
|---|---|
| 52-week range | 319.40 – 580.00 |
| Return, 1 month / 3 months | +1.0% / +1.4% |
| Return, 1 year / 3 years | +51.6% / +0.3% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 44.7% |
| Worst drawdown (1 year) | -19.1% |
| Average daily value traded | 994.69M GBX |
| Dividend yield | 3.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Tate and Lyle is a food ingredients company based in the United Kingdom. It supplies sweeteners, texturants, stabilisers and other specialty ingredients to food and beverage manufacturers, along with products for animal feed and industrial uses. The company also makes sucralose, a low-calorie sweetener, and serves customers across many countries through its ingredient solutions and primary products businesses.
Tate & Lyle PLC trades under the code TATE on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Tate & Lyle PLC (TATE) trades on the London Exchange in UK. It last closed at GBX 564.50 on 23 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 104 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 51.6% and over the last three months it rose 1.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.7% | ||
| From 52-week high | -0.8% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 1.4% | ||
| 6-month return | 62.7% | ||
| 12-month return, skipping the last month | 50.1% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 44.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.1% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 994.69M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 72 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 3.5% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +0.1% |
|---|---|
| 1 month | +1.0% |
| 3 months | +1.4% |
| 6 months | +62.7% |
| 1 year | +51.6% |
| 3 years | +0.3% |
| 5 years | −1.4% |
Signals
| 50-day / 200-day average | 558.41 / 467.80 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.74 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Jun 2026 | GBP 0.1320 |
| 20 Nov 2025 | GBP 0.0660 |
| 19 Jun 2025 | GBP 0.1340 |
| 21 Nov 2024 | GBP 0.0640 |
| 20 Jun 2024 | GBP 0.1290 |
| 23 Nov 2023 | GBP 0.0620 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.